Merck + Co., Inc.

Other

Banyu Pharmaceutical Co. Ltd

Carina P Tan

Andrew D Howard

Douglas J MacNeil

Roy G Smith

Margaret A Cascieri

Kathleen A Sullivan

Catherine D Strader

David L Linemeyer

David H Weinberg

Lin-Lin Shiao

Arthur A Patchett

Leonardus H T Van Der Ploeg

Kevin R Lynch

Scott D Feighner

Hideki Sano

Karen Kulju McKee

Sheng-Shung Pong

Oksana C Palyha

Lee F Kolakowski, Jr

The present invention identifies the presence of MCH-2R in the dog, ferret and rhesus monkey. MCH-2R is a G-protein coupled receptor that responds to MCH and is distinct from MCH-1R. MCH-2R polypeptide and nucleic acid sequences related to the dog, ferret, and rhesus monkey MCH-2R are described herein along with uses of such polypeptides and nucleic acids.

Rhesus monkey, dog and ferret melanin-concentrating hormone type 2 receptor

The motilin receptor has been isolated and cloned, and nucleic acid sequences are given. Two spice variants have been identified. Also, assays for motilin receptor ligands are given. The identification of the cloned motilin receptor may be used to screen and identify compounds which bind to the receptor for use in a variety of gastric conditions, including gastric motility disorders.

Cloning and identification of the motilin receptor

The present invention features polypeptides and nucleic acids related to a dog MCH receptor and uses of such polypeptides and nucleic acids. The dog MCH receptor is a G protein coupled receptor whose activity is stimulated by MCH binding.

Dog melanin-concentrating hormone receptor

A novel canine cDNA sequence that encodes the canine growth hormone secretagogue receptor (GHSR) protein is provided. Also provided is canine GHSR protein encoded by the novel cDNA sequence. Methods of expressing canine GHSR protein in recombinant systems are provided. Also provided are methods for identifying agonists and antagonists of the canine GHSR.

Canine growth hormone secretagogue receptor

A new galanin receptor, GALR2, is described. Also provided are nucleic acids encoding same and various assays to identify ligands particular to said receptor. Ligands so identified are useful for the treatment of obesity, treatment of pain, and treatment of cognitive disorders.

Galanin receptor (GALR2) binding assay

A new galanin receptor, GALR3, is described. Also provided are nucleic acids encoding same and various assays to identify ligands particular to said receptor. Ligands so identified are useful for the treatment of obesity, treatment of pain, and treatment of cognitive disorders.

Nucleotide encoding human galanin receptor 3 (GALR3)

Nucleic acid encoding mouse galanin receptor (GALR2)

Nucleic acid encoding rat galanin receptor (GALR2)

Neuropeptide Y receptor

A novel mammalian neuropeptide Y receptor and method of making the receptor are provided. The invention includes DNA encoding the receptor, the receptor, assays employing the receptor, cells expressing the receptor, antibodies which bind specifically to the receptor, RNA encoded by the DNA sequence or its complementary sequence, and single-stranded DNA with a sequence complementary to the RNA which encodes the receptor. The receptor and assays employing the receptor are useful for identifying compounds which bind to the receptor, including specific modulators of the receptor. Such compounds are useful for treating a variety of disease conditions, including obesity, diabetes, anxiety, hypertension, cocaine withdrawal, congestive heart failure, memory enhancement, cardiac and cerebral vasospasm, pheochromocytoma and ganglioneuroblastoma, and Huntington's, Alzheimer's and Parkinson's diseases.

Growing community of inventors

Metuchen, NJ, United States of America

Carina P Tan